PRESCIENT THERAPEUTICS
Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.
PRESCIENT THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
1999-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.prescienttherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+61396927222
Email Addresses:
[email protected]
Total Funding:
3 M USD
Technology used in webpage:
SPF Amazon Amazon Ohio Region NameBright
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.prescienttherapeutics.com
- Host name: ec2-18-119-154-66.us-east-2.compute.amazonaws.com
- IP address: 18.119.154.66
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Prescient Therapeutics" on Search Engine
Home - PTX Therapeutics
Apr 9, 2024 Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies.See details»
About Us - PTX Therapeutics
Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies. Prescient’s technologies emanate from prestigious world class centres including Yale, Penn, Oxford and Moffitt.See details»
Prescient Therapeutics - Wikipedia
Prescient Therapeutics. Prescient Therapeutics Ltd is a clinical stage oncology company. The company is focused on the development of a universal CAR-T platform (OmniCAR), enhanced CAR-T cell manufacturing & function (CellPryme) and on two small molecule drug targeted therapies (PTX-100 & PTX-200).See details»
Prescient Therapeutics - Crunchbase Company Profile & Funding
Company Type For Profit. Contact Email [email protected]. Phone Number +61396927222. Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.See details»
Prescient Therapeutics | LinkedIn
About us. Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies. Cell Therapies...See details»
News and Media - PTX Therapeutics
May 21, 2024 Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies. CONTACT P: +61 3 9692 7222See details»
Investor Centre - PTX Therapeutics
Mar 25, 2024 About Prescient Therapeutics. Prescient Therapeutics develops personalised therapies to conquer cancer. It has a broad portfolio of well advanced assets developed with world-leading partners including Yale, UPenn, Oxford, Moffitt & Peter MacCallum. Prescient’s first in class targeted therapy – PTX-100 – is currently in clinical ...See details»
Prescient Therapeutics - PTX Therapeutics
Prescient Therapeutics (ASX: PTX) Tuesday, 4th October 12pm (AEDT) Please join Prescient CEO and managing director Steven Yatomi-Clarke for an investor briefing. In this session, Steven will discuss: How PTX is taking the …See details»
Prescient Therapeutics hopes to accelerate bid for US FDA study ...
Mar 21, 2023 Prescient Therapeutics (ASX:PTX) will seek approval from the US Food and Drug Administration (FDA) for an accelerated approval study after its Phase 1b clinical trial of PTX-100 in relapsed and refractory T-cell …See details»
Prescient Therapeutics Ltd, PTX:ASX summary - FT.com
PTX:ASX. Actions. Health Care Pharmaceuticals and Biotechnology. Price (AUD) 0.045. Today's Change -0.001 / -2.17% Shares traded 580.84k. 1 Year change -44.44% Beta 1.6408. Data delayed at least 20...See details»
News & media - PTX Therapeutics
Mar 7, 2024 Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study. January 10, 2024. Proactive Investors.See details»
Here's Why We're Not Too Worried About Prescient Therapeutics…
Sep 28, 2023 When Prescient Therapeutics last reported its balance sheet in June 2023, it had zero debt and cash worth AU$22m. Importantly, its cash burn was AU$6.2m over the trailing twelve months. That...See details»
Technology - PTX Therapeutics
Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies.See details»
Prescient Therapeutics Ltd (PTX) Stock Price & News - Google
Get the latest Prescient Therapeutics Ltd (PTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.See details»
Prescient Therapeutics - Contacts, Employees, Board Members, …
Prescient Therapeutics. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 4. Contacts 5. About. Prescient Therapeutics has 4 current employee profiles, including Founder & Chief Scientific Officer Said Sebti. Contacts. Job Department. Protected Content. CEO and Managing Director.See details»
Prescient Therapeutics - Funding, Financials, Valuation & Investors
Prescient Therapeutics is a biopharmaceutical company, discovers and develops novel immunotherapeutic products for the treatment of chronic.See details»
Investor Centre - PTX Therapeutics
Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies. CONTACT. P: +61 3 9692 7222. F: +61 3 9077 9233. E: [email protected]. Welcome to the Prescient Therapeutics Investor Centre.See details»
Organization | Prescient Therapeutics, Ltd. - CDEK
Prescient Therapeutics, Ltd. Report issue. For profit Phase 1 Phase 2. Founded: Melbourne Australia (1987 ... Organization Overview. First Clinical Trial. 2002 NCT00332930. First Marketed Drug. None ...See details»
Prescient Therapeutics Share Purchase Plan - PTX Therapeutics
Prescient Therapeutics Limited (ASX: PTX) has launched a Share Purchase Plan (SPP) targeting to raise $8,000,000 at $0.175/share, representing a discount of approximately 14.6% to Prescient’s 5-day VWAP (calculated on 23rd August 2022). Use of Funds.See details»
Share Price and Announcements - PTX Therapeutics
Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies. CONTACT P: +61 3 9692 7222See details»